Awaiting FDA OK for OVA1 Test, Vermillion Hires Bank to Explore ‘Alternatives’ for Dx

The bank, ThinkPanmure, will help Vermillion identify and evaluate “strategic alternatives intended to enhance the potential” of the test, called OVA1, as well as for its diagnostic for peripheral arterial disease, VASCLIR. Vermillion did not define the alternatives.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.